Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Castelo Branco

11 clinical trials in Castelo Branco, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Castelo Branco at a glance
11
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

11 trials in Castelo Branco

Open in trial search

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides farinae enriched allergoid, mannan-conjugated, polymerised
  • Sponsor:Inmunotek S.L.

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on MK-2060 for Preventing Blood Clots in Dialysis Patients with End-Stage Kidney Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:MK-2060
  • Sponsor:Merck Sharp & Dohme LLC

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Castelo Branco

What the registry says about research in the country

01 Immune System Diseases

Clinical research in Castelo Branco is concentrating on immune system diseases, specifically allergic rhinoconjunctivitis with or without asthma triggered by grass and olive pollen. The studies evaluate the therapeutic benefit of allergen immunotherapy using a mobile symptom‑medication score to compare active treatment against placebo.

  • Grass and olive allergen immunotherapy administered over multiple injections
  • Use of a mobile application to capture combined symptom and medication scores
  • Placebo‑controlled, double‑blind design to assess clinical efficacy
  • Evaluation of treatment impact during peak pollen seasons

Findings aim to confirm that targeted immunotherapy can reduce allergy burden and improve quality of life for patients with seasonal respiratory allergies.

02 Respiratory Tract Diseases

The respiratory tract diseases portfolio in Castelo Branco focuses on allergic rhinitis and controlled asthma associated with grass pollen exposure. Trials measure how allergen immunotherapy modifies airway reactivity and medication use, employing both double‑blind and open‑label phases to capture comprehensive efficacy data.

  • Assessment of clinical efficacy of grass allergen immunotherapy across concentrations
  • Change in allergen dose required for a positive challenge test after treatment
  • Combined symptom‑medication score collected via mobile app during pollen peaks
  • Comparison of active therapy with placebo to determine treatment benefit

The goal is to demonstrate that immunotherapy can sustainably lessen respiratory symptoms and reduce reliance on rescue medication for individuals with seasonal allergies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.